Dosage Appropriacy Evaluation of Oral Venlafaxine Related to CYP2D6 Genotype Using Physiologically Based Pharmacokinetic (PBPK) Model

被引：0
|
作者：
Cho, Changkeun [1 ]
机构：
[1] Sungkyunkwan Univ, Seoul, South Korea
来源：
FASEB JOURNAL | 2020年 / 34卷
关键词：
D O I：
10.1096/fasebj.2020.34.s1.03769
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression
    Men, Xiaoyu
    Taylor, Zachary L.
    Marshe, Victoria S.
    Blumberger, Daniel M.
    Karp, Jordan F.
    Kennedy, James L.
    Lenze, Eric J.
    Reynolds, Charles F.
    Stefan, Cristiana
    Mulsant, Benoit H.
    Ramsey, Laura B.
    Mueller, Daniel J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 (05) : 1065 - 1074
  • [32] Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model
    Xue, Caifu
    Zhang, Xunjie
    Cai, Weimin
    PHARMACEUTICS, 2018, 10 (01):
  • [33] Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions
    Huang, Weize
    Nakano, Mariko
    Sager, Jennifer
    Ragueneau-Majlessi, Isabelle
    Isoherranen, Nina
    DRUG METABOLISM AND DISPOSITION, 2017, 45 (11) : 1156 - 1165
  • [34] Quantitative assessment of the effect of CYP2D6 genotype on tamoxifen metabolism: A model for CYP2D6 genotype-phenotype studies.
    Borges, S
    Desta, Z
    Jin, Y
    Li, L
    Skaar, TC
    Flockhart, DA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P34 - P34
  • [35] Drug-drug interaction between hydroxybupropion and venlafaxine: A pharmacokinetic study on CYP2D6
    Theisen, S.
    Scherf-Clavel, M.
    Deckert, J.
    Menke, A.
    Unterecker, S.
    PHARMACOPSYCHIATRY, 2020, 53 (02) : 98 - 98
  • [36] Drug-drug interaction between hydroxybupropion and venlafaxine - a pharmacokinetic study on CYP2D6
    Zioris, G.
    Warrings, B.
    Heiduk, S.
    Deckert, J.
    Unterecker, S.
    Scherf-Clavel, M.
    PHARMACOPSYCHIATRY, 2024, 57 (02) : 92 - 92
  • [37] Physiologically Based Pharmacokinetic Modeling to Unravel the Drug-gene Interactions of Venlafaxine: Based on Activity Score-dependent Metabolism by CYP2D6 and CYP2C19 Polymorphisms
    Chaozhuang Shen
    Hongyi Yang
    Wenxin Shao
    Liang Zheng
    Wei Zhang
    Haitang Xie
    Xuehua Jiang
    Ling Wang
    Pharmaceutical Research, 2024, 41 : 731 - 749
  • [38] PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING FOR ASSESSMENT OF ELIGLUSTAT INTERACTION POTENTIAL WITH CYP2D6 AND CYP3A INHIBITORS.
    Chen, J.
    Turpault, S.
    Kalamaluru, V.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S62 - S62
  • [39] Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations
    Elmokadem, Ahmed
    Bruno, Christopher D.
    Housand, Conrad
    Jordie, Eric Burroughs
    Chow, Christina R.
    Lesko, Lawrence J.
    Greenblatt, David J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (01): : 66 - 75
  • [40] Physiologically Based Pharmacokinetic Modeling to Unravel the Drug-gene Interactions of Venlafaxine: Based on Activity Score-dependent Metabolism by CYP2D6 and CYP2C19 Polymorphisms
    Shen, Chaozhuang
    Yang, Hongyi
    Shao, Wenxin
    Zheng, Liang
    Zhang, Wei
    Xie, Haitang
    Jiang, Xuehua
    Wang, Ling
    PHARMACEUTICAL RESEARCH, 2024, 41 (04) : 731 - 749
12345